Raoul S. Concepcion, MD, FACS, Author at Grand Rounds in Urology

Raoul S. Concepcion, MD, FACS

U.S. Urology Partners

Nolensville, Tennessee

Raoul S. Concepcion, MD, FACS, is the Chief Science Officer of U.S. Urology Partners in Nolensville, Tennessee. He was a resident in General Surgery and Urology at Vanderbilt University from 1984-1990, and later served as a Clinical Associate Professor of Urology there.

Dr. Concepcion’s clinical interests revolve around advanced prostate and bladder cancer management. He is a past President of LUGPA. Along with two other urologists, he founded CUSP, a urologic research consortium in the United States. Additionally, he is an advisor and/or speaker for many companies, including Dendreon, Pfizer, Astellas, Amgen, Cellay, and Janssen, and has served as editor for Urologists in Cancer Care.

Disclosures:

Speakers Bureau Member: Astellas, Amgen, Pfizer
Advisory Committee Member: Dendreon, Clovis
Consultant: Merck, Invitae, CUSP PharmaTech Consulting, Cellay, Sun Pharmaceutical Industries, Integra Connect
Honorarium Recipient: Dendreon, Clovis, Merck, Invitae, CUSP PharmaTech Consulting, Cellay, Sun Pharmaceutical Industries, Integra Connect

Talks by Raoul S. Concepcion, MD, FACS

Upper Tract Urothelial Cancer: What You Need to Know

Posted by Raoul S. Concepcion, MD, FACS | May 2019

Raoul S. Concepcion, MD, FACS, provides an overview of the epidemiology of upper tract urothelial carcinoma (UTUC). He discusses the most recent efforts in improving management for the disease, particularly focusing on neoadjuvant chemotherapy when treating high-grade tumors and nonsurgical ways to combat low-grade UTUC.

AR-V7 Predicts Response in CRPC

Posted by Raoul S. Concepcion, MD, FACS | Apr 2019

Raoul S. Concepcion, MD, FACS, emphasizes the need for more effective biomarkers when determining adequate treatment for patients with castrate-resistant prostate cancer (CRPC). Concurrently, he compares the findings of studies exploring various options, including the AR-V7 splice variant.

Current Challenges in Upper Tract Urothelial Cancer

Posted by Raoul S. Concepcion, MD, FACS | Oct 2018

Raoul S. Concepcion, MD, FACS, provides a brief overview of the background, incidence, and epidemiology of upper tract urothelial carcinoma (UTUC). He then discusses indications for nephroureterectomy with a cuff of bladder and possible methods for management that would be less invasive for low-grade UTUC patients.

Updates on Upper Tract Urothelial Cancer

Posted by Raoul S. Concepcion, MD, FACS | Oct 2018

Raoul S. Concepcion, MD, FACS, discusses the challenge of managing upper tract urothelial cancer (UTUC) while avoiding overtreatment. Although nephroureterectomy is an appropriate treatment for high grade tumors, urologists should utilize localized therapy and avoid surgery in low-grade UTUC.

Immunotherapy 101 for the Urologist

Posted by Raoul S. Concepcion, MD, FACS | Apr 2018

Raoul S. Concepcion, MD, summarizes the mechanism of action behind the immune response to cancer. He also provides an update on the current and emerging immunotherapies for cancer treatment, including vaccines, checkpoint inhibitors, CAR T-cell therapies, viral vectors, and adoptive cell therapy.